SODIUM CHLORIDE 0.45% INJ 450 MG / 100 ML
SODIUM CHLORIDE : 450 MG / 100 ML · DIN 00060186 · BAXTER CORPORATION
Health Canada status: MARKETED
What is SODIUM CHLORIDE 0.45% INJ?
SODIUM CHLORIDE 0.45% INJ 450 MG / 100 ML contains SODIUM CHLORIDE : 450 MG / 100 ML. It is listed in the Health Canada Drug Product Database under DIN 00060186, held by BAXTER CORPORATION, supplied as LIQUID for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 31-Dec-1990. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is SODIUM CHLORIDE 0.45% INJ used for?
Source of water and electrolytes; vehicle or diluent for compatible products for parenteral administration.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 00060186 |
|---|---|
| Brand name | SODIUM CHLORIDE 0.45% INJ |
| Generic / active ingredient | SODIUM CHLORIDE : 450 MG / 100 ML |
| Manufacturer | BAXTER CORPORATION |
| Strength | 450 MG / 100 ML |
| Dosage form | LIQUID |
| Route of administration | INTRAVENOUS |
| Schedule | Ethical |
| ATC code | B05XA03 SODIUM CHLORIDE |
| AHFS class | 40:12.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 31-Dec-1990 |
| Original market date | 1990-12-31 00:00:00 |
How is it administered?
Individualized by physician based on age, weight, and clinical condition. Administered intravenously using sterile equipment. Inspect for particulate matter before use.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at 15°C to 25°C.
How is it supplied?
Viaflex plastic containers (1000 mL). Small volumes (less than 100 mL) used as diluents.
Contraindications
Hypersensitivity to this drug or to any ingredient in the formulation or component of the container.
Warnings and precautions
Risk of fluid/solute overload, hyponatremia, and hemolysis. Use with care in patients with congestive heart failure, edema, or renal insufficiency. Risk of air embolism.
Is SODIUM CHLORIDE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Active — reported by SANDOZ CANADA INCORPORATED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code B05XA03 SODIUM CHLORIDE. 11 of 37 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| 0.45% SODIUM CHLORIDE INJECTION USP | 4.5 MG | SOLUTION | B. BRAUN MEDICAL INC | MARKETED | DIN 01927949 |
| 0.9% SODIUM CHLORIDE INJECTION | 500ML | Solution | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02395150 |
| 0.9% SODIUM CHLORIDE INJECTION USP | 0.9 % | SOLUTION | B. BRAUN MEDICAL INC | MARKETED | DIN 01924303 |
| 0.9% SODIUM CHLORIDE INJECTION, USP | 900 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 00060208 |
| 20% SODIUM CHLORIDE INJECTION, BP | 20 % | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02514184 |
| 5% SODIUM CHLORIDE INJECTION USP | 5 G / 100 ML | SOLUTION | B. BRAUN MEDICAL INC | MARKETED | DIN 01928007 |
| SODIUM CHLORIDE 3% INJ | 3 G / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 00060232 |
| SODIUM CHLORIDE INJECTION USP | 9 MG | SOLUTION | ICU MEDICAL CANADA INC | MARKETED | DIN 00037842 |
| SODIUM CHLORIDE INJECTION USP | 9 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 00037796 |
| SODIUM CHLORIDE INJECTION, USP | 234 MG | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02139510 |
Who else supplies SODIUM CHLORIDE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. SODIUM CHLORIDE appears in 5432 registered pack listings across 10 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.